Skip to main content
Premium Trial:

Request an Annual Quote

Caliper Shares Jump 8 Percent as Xenogen Unit Pens Target Validation Deal With Schering-Plough

NEW YORK (GenomeWeb News) - Caliper Life Sciences business unit Xenogen Biosciences will collaborate with Schering-Plough Research Institute to validate targets in drug discovery, Xenogen said today.
News of the alliance caused shares in Caliper to trade up 8.07 percent, or $.37, at $4.97 mid-afternoon today.
Xenogen Biosciences will use its serial phenotyping compression technology to characterize high value targets. The technology relies on a battery of more than 85 pharmacologically validated bioassays.
The agreement expands on a previous gene targeting agreement to create standard and conditional gene knockouts.
Financial details were not disclosed.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.